RxDoctor Payments Data

Jacquelyn Showalter

Family · Conneaut, OHNPI 1639884000

Payments from drug & device makers

$1,578in general payments, 2019–2025

Across 84 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$486
  • Novo Nordisk$393
  • Lilly USA, LLC$161
  • Pfizer$111
  • GSK$75
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$55
  • plus $298 from 12 others

What the payments were for

  • Food & beverage$1,578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,578 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$18,369
Medicare patients
162
Services billed
281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide52$61,460
JardianceEmpagliflozin77$57,418
OzempicSemaglutide55$52,008
FarxigaDapagliflozin Propanediol65$47,806
MounjaroTirzepatide36$35,846
RybelsusSemaglutide19$20,940
EliquisApixaban19$16,030
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$14,521
Spiriva RespimatTiotropium Bromide16$8,155
Breo ElliptaFluticasone/Vilanterol19$7,657
DapagliflozinDapagliflozin Propanediol13$6,531
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,525
Omeprazole148$2,088
Atorvastatin Calcium281$1,555
Pantoprazole Sodium141$1,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$161$97,30688 claims
Novo NordiskOzempic, Rybelsus$393$72,94874 claims
Boehringer IngelheimJardiance, Spiriva Respimat$30$65,57393 claims
AstraZenecaFarxiga$486$47,80665 claims
GSKTrelegy Ellipta, Breo Ellipta$75$22,17832 claims
PfizerEliquis$111$16,03019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Conneaut

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →